Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28969409 | 0.94 | MAPK1 (0.69) | MAPK1LMNANLRP3HPGDALDH1A1 | |
| SCHEMBL1024875 | 0.91 | MAPK1 (0.61) | MAPK1LMNANLRP3HPGDALDH1A1 | |
| SCHEMBL3596907 | 0.91 | MAPK1 (0.76) | MAPK1LMNANLRP3HPGDALDH1A1 | |
| SCHEMBL1023754 | 0.90 | MAPK1 (0.60) | MAPK1LMNANLRP3HPGDALDH1A1 | |
| SCHEMBL1024873 | 0.89 | NLRP3 (0.65) | MAPK1NLRP3HPGDALDH1A1NPC1 | |
| SCHEMBL1025186 | 0.89 | MAPK1 (0.59) | MAPK1LMNANLRP3HPGDALDH1A1 | |
| SCHEMBL1023696 | 0.89 | MAPK1 (0.59) | MAPK1LMNANLRP3HPGDALDH1A1 | |
| SCHEMBL1022068 | 0.89 | MAPK1 (0.59) | MAPK1LMNANLRP3HPGDALDH1A1 | |
| SCHEMBL1954916 | 0.86 | LMNA (0.74) | MAPK1LMNANLRP3HPGDALDH1A1 | |
| SCHEMBL28969405 | 0.86 | MAPK1 (0.59) | MAPK1LMNANLRP3HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637445-B2 | Isocyanate production process using composition containing carbamic acid ester and aromatic hydroxy compound, and composition for transfer and storage of carbamic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2017-05-02 | — | — | US | disclosed |
| EP-2147909-B1 | METHOD FOR PRODUCTION OF ISOCYANATE USING COMPOSITION COMPRISING CARBAMIC ACID ESTER AND AROMATIC HYDROXY COMPOUND, AND COMPOSITION FOR TRANSPORT OR STORAGE OF CARBAMIC ACID ESTER | ASAHI CHEMICAL IND (JP) | 2016-12-14 | — | — | EP | disclosed |
| US-20150259279-A1 | Isocyanate Production Process Using Composition Containing Carbamic Acid Ester and Aromatic Hydroxy Compound, and Composition for Transfer and Storage of Carbamic Acid Ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-09-17 | — | — | US | disclosed |
| US-9056819-B2 | Isocyanate production process using composition containing carbamic acid ester and aromatic hydroxy compound, and composition for transfer and storage of carbamic acid ester | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2015-06-16 | — | — | US | disclosed |
| EP-2088138-B1 | Process for producing isocyanate | ASAHI KASEI CHEMICALS CORP (JP) | 2013-02-27 | — | — | EP | disclosed |
| US-8362293-B2 | Process for producing isocyanates | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2013-01-29 | — | — | US | disclosed |
| US-8053595-B2 | Process for producing isocyanates | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2011-11-08 | — | — | US | disclosed |
| EP-2088137-B1 | A PROCESS FOR PRODUCING ISOCYANATES | ASAHI KASEI CHEMICALS CORP (JP) | 2011-01-12 | — | — | EP | disclosed |
| US-20100113823-A1 | ISOCYANATE PRODUCTION PROCESS USING COMPOSITION CONTAINING CARBAMIC ACID ESTER AND AROMATIC HYDROXY COMPOUND, AND COMPOSITION FOR TRANSFER AND STORAGE OF CARBAMIC ACID ESTER | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100069665-A1 | PROCESS FOR PRODUCING ISOCYANATES | AHAHI KASEI CHEMICALS CORPORATION (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100029981-A1 | PROCESS FOR PRODUCING ISOCYANATES | ASAHI KASEI CHEMICALS CORPORATION (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2147909-A1 | METHOD FOR PRODUCTION OF ISOCYANATE USING COMPOSITION COMPRISING CARBAMIC ACID ESTER AND AROMATIC HYDROXY COMPOUND, AND COMPOSITION FOR TRANSPORT OR STORAGE OF CARBAMIC ACID ESTER | Asahi Kasei Chemicals Corporation (JP) | 2010-01-27 | — | — | EP | disclosed |
| EP-2088137-A1 | METHOD FOR PRODUCING ISOCYANATE | Asahi Kasei Chemicals Corporation (JP) | 2009-08-12 | — | — | EP | disclosed |
| EP-2088138-A1 | PROCESS FOR PRODUCING ISOCYANATE | Asahi Kasei Chemicals Corporation (JP) | 2009-08-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113823-A1 | ISOCYANATE PRODUCTION PROCESS USING COMPOSITION CONTAINING CARBAMIC ACID ESTER AND AROMATIC HYDROXY COMPOUND, AND COMPOSITION FOR TRANSFER AND STORAGE OF CARBAMIC ACID ESTER | PAH, APEH, CPS1 | MAPK1 3960/4885LMNA 3875/4885NLRP3 472/4885 |
| US-20100029981-A1 | PROCESS FOR PRODUCING ISOCYANATES | PAH, ALKBH3, GRHPR | MAPK1 2340/4885LMNA 4196/4885NLRP3 2178/4885 |
| US-20100069665-A1 | PROCESS FOR PRODUCING ISOCYANATES | CPS1, IDH2, PHGDH | MAPK1 3838/4885LMNA 4077/4885NLRP3 3782/4885 |
| US-20150259279-A1 | Isocyanate Production Process Using Composition Containing Carbamic Acid Ester and Aromatic Hydroxy Compound, and Composition for Transfer and Storage of Carbamic Acid Ester | PAH, APEH, CPS1 | MAPK1 3960/4885LMNA 3875/4885NLRP3 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.